Innovating antibodies, improving lives

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.


financial news 260x1732019 Full Year Financial Results

Genmab will report its 2019 Full Year financial results after market close on February 19. An investor conference call to discuss the results will be held at 6:00 PM CET / 12:00 PM EST on February 19. To join the call by phone, dial one of the following numbers and provide confirmation code 4887886: +45 32728042 in Denmark, +44 2071 928000 in the UK or +1 631 510 7495 in the US. Click here to listen to the webcast. 


join our team_260x173Career Opportunities at Genmab

Genmab is seeking new employees to join our team. Visit our Careers webpages to explore current vacancies, learn about our culture and meet some of our team members. Click here to visit Genmab's page on LinkedIn.    



Investorportal sign on_260x173InvestorPortal

To register your email address for electronic shareholder communication or to update your settings, log on to the InvestorPortal.


Latest news

Our Strategy

  • Click here to watch a video about our strategy.

Strategy Film

Stock Info